Edgar Filing: Quinn Anthony G. - Form 4

Quinn Antho Form 4 February 20,												
										OMB APPROVAL		
Check this	UNITE	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES										
if no long subject to Section 10 Form 4 or Form 5	er STATE 5.											
obligation may conti <i>See</i> Instru 1(b).	^{is} nue. Section 1	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type R	esponses)											
			2. Issuer Name and Ticker or Trading Symbol Aeglea BioTherapeutics, Inc.					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
		AC1 11										
	(First) EA PEUTICS, IN PRESSWAY,		3. Date of (Month/D 02/15/20	-	ansaction			X Director X Officer (give below) In		Owner er (specify		
	(Street)	Street) 4. If Amendment Filed(Month/Day/			-			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
AUSTIN, T	X 78746								Iore than One Re			
(City)	(State)	(Zip)	Table	e I - Non-E	Derivative S	Securi	ties Acq	uired, Disposed of	f, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction D (Month/Day/Yea	ar) Executio any	med n Date, if Day/Year)	Transactio Code (Instr. 8)	on(A) or Dia (Instr. 3, 4	sposed 4 and 5 (A) or	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common Stock	02/15/2018			Code V M	Amount 15,211	(D) A	Price \$ 5.46	50,620	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Quinn Anthony G. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	\$ 5.46	02/15/2018		М	15,211	<u>(1)</u>	03/17/2026	Common Stock	15,211

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Quinn Anthony G. C/O AEGLEA BIOTHERAPEUTICS, INC. 901 S. MOPAC EXPRESSWAY, SUITE 250 AUSTIN, TX 78746	Х		Interim CEO				
Signatures							
/s/ Charles N. York II, by power of attorney	02/20/	2018					
**Signature of Reporting Person	Date	e					
Explanation of Responses:							

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The stock option vested and became exercisable as to 1/36th of the shares subject to the option on April 3, 2016, and thereafter vests as to (1) 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.